Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Lawrence

Showing results (821-830 of 884) with videos related to

Pageof 89
Sort By:
Breast Cancer Research and Treatment|November 13, 2017
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG OncologyEleftherios P Mamounas, Gong Tang, Soonmyung Paik, et al.
JAMA Oncology|November 5, 2016
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 TrialPatrick G Gavin, Nan Song, S Rim Kim, et al.
Cancer Discovery|June 15, 2013
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer preventionJames N Ingle, Mohan Liu, D Lawrence Wickerham, et al.
Cancer Research|January 13, 1998
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogeneticsM A Caligiuri, M P Strout, D Lawrence, et al.
Psychiatry Research|August 18, 2015
The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerationsSomaia Mohamed, Gary R Johnson, Julia E Vertrees, et al.
Seminars in Oncology|August 15, 1998
Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacementJ A Roth, S G Swisher, J A Merritt, et al.
The Lancet. Oncology|December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialEleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2011
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancerChungyeul Kim, Gong Tang, Katherine L Pogue-Geile, et al.
Journal of the National Cancer Institute|March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast CancerRim S Kim, Nan Song, Patrick G Gavin, et al.
JAMA|June 7, 2006
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trialVictor G Vogel, Joseph P Costantino, D Lawrence Wickerham, et al.
Pageof 89

Showing results (821-830 of 884) with videos related to

Sort By:
Pageof 89
Breast Cancer Research and Treatment|November 13, 2017
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG OncologyEleftherios P Mamounas, Gong Tang, Soonmyung Paik, et al.
JAMA Oncology|November 5, 2016
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 TrialPatrick G Gavin, Nan Song, S Rim Kim, et al.
Cancer Discovery|June 15, 2013
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer preventionJames N Ingle, Mohan Liu, D Lawrence Wickerham, et al.
Cancer Research|January 13, 1998
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogeneticsM A Caligiuri, M P Strout, D Lawrence, et al.
Psychiatry Research|August 18, 2015
The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerationsSomaia Mohamed, Gary R Johnson, Julia E Vertrees, et al.
Seminars in Oncology|August 15, 1998
Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacementJ A Roth, S G Swisher, J A Merritt, et al.
The Lancet. Oncology|December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialEleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2011
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancerChungyeul Kim, Gong Tang, Katherine L Pogue-Geile, et al.
Journal of the National Cancer Institute|March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast CancerRim S Kim, Nan Song, Patrick G Gavin, et al.
JAMA|June 7, 2006
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trialVictor G Vogel, Joseph P Costantino, D Lawrence Wickerham, et al.
Pageof 89